WikiLeaks cable: No quick fix for pharmaceutical market
This is one of the diplomatic cables about New Zealand held by Wikileaks.
December 15, 2004 SUBJECT: NEW ZEALAND'S PHARMACEUTICAL MARKET: NO QUICK FIX
Classified by: DCM David R. Burnett. Reasons: 1.4 (b) and (d).
1. (SBU) Summary: After trying in vain for years to persuade the New Zealand government to change its restrictive
pricing policies on pharmaceuticals, the drug industry is taking another tack: reaching out to patient groups with
information designed to bolster their demands for cutting-edge drugs not already covered by government subsidy. Several
U.S. drug companies also hold out hope that a New Zealand-U.S. free-trade agreement could be a lever for improving their
access to New Zealand's pharmaceutical market.
2. (C) The government contends it already is increasing drug availability by boosting the budget for pharmaceutical
purchases over the next three years. In actuality, its spending on drugs in real terms is declining. U.S. pharmaceutical
companies continue to struggle in what they view as one of the most restricted free-world markets. They are cutting
local staff, and they are slashing investment in New Zealand-based research and development. Attempting to make inroads
against a government mindset that is hostile to the drug industry, post is working with the industry to identify
speakers and engage in other public diplomacy efforts that could help educate New Zealanders on the benefits of gaining
access to a wider range of effective pharmaceuticals. End summary.
Limited prices, limited access
3. (U) Spending in New Zealand on government-subsidized pharmaceuticals has risen by less than three percent per year on
average during the last decade, compared to 14 percent per year in Australia. Only six new drugs a year were approved on
average over the last three years for reimbursement in New Zealand, compared to about 30 drugs in Australia. The New
Zealand government nevertheless asserts that it now is increasing the budget for pharmaceuticals sufficiently to
subsidize more new medicines.
4. (U) In fact, the pharmaceutical budget rose this fiscal year (ending June 30) by 4.4 percent, to NZ $541 million (US
$380 million), with planned increases in the following two years of .5 percent and 1.9 percent. The smaller increases in
the 2006-2007 and 2007-2008 budget years were based on the expectation that a number of expensive drugs will go off
patent, according to Stuart Bruce, manager of communications and external relations for the Pharmaceutical Management
Agency (Pharmac), a stand-alone Crown entity.
5. (U) Exempt from New Zealand's competition law, Pharmac acts as a single buyer, or monopsony, that decides which
medicines will be subsidized by the government and how much reimbursement will be paid for each pharmaceutical. In some
cases, the supplier is not allowed to set a drug price higher than the subsidy as determined by Pharmac. The agency also
puts a cap on the amount of a drug to be purchased at a certain price. Its decisions effectively allocate about 73
percent of New Zealand's spending on prescription drugs.
Pharmac does not directly handle funding for the government's drug subsidy. Those funds are dispersed by the national
health care systems' 21 district health boards to the pharmaceutical suppliers after a prescribed drug is dispensed to
the consumer.
6. (SBU) Bruce noted that Pharmac always under-spends its budget because government policy prohibits exceeding it. That
means that actual public spending on pharmaceuticals is likely to remain relatively flat or even decline in real terms
over the next three years. Further explaining why Pharmac spends less than planned, Bruce said that some patients do not
pick up their prescriptions because of co-payment delays. Spending projections also are based on the assumption that
patients will consume their entire prescription. Since pharmacists receive a fee each time they dispense a medication,
they usually break a prescription into installments, and some patients do not purchase an entire prescription.
7. (C) Pharmac designated 15 new products for reimbursement the past fiscal year, up from three new drugs in 2002-2003.
U.S. pharmaceutical firms we talked to, however, point out that only one of those new medicines is freely available.
Access to the other medicines is available only after doctors make special application or when patients meet specific
criteria. For example, only specialists can prescribe a new treatment for diabetes. The drug's manufacturer believes
2,000 to 3,000 of the more than 100,000 diabetics in New Zealand could benefit from the medicine. But with just 50
specialists nationwide, most patients are under the care of general practitioners, and obtaining the drug is difficult.
Another company reported that six out of 10 applications by doctors for reimbursement for its schizophrenia drug are
rejected.
8. (C) The industry also criticizes Pharmac for a lack of transparency in its funding decisions. One U.S. company spent
more than three years negotiating with Pharmac to gain public funding for a schizophrenia treatment. Without explanation
(none is required), Pharmac broke off those discussions this year.
9. (U) The New Zealand industry group Researched Medicines Industry (RMI) said in a statement that Pharmac is using
"smoke and mirrors" to portray itself as widening New Zealanders' access to pharmaceuticals. Since leading-edge
medicines generally are not subsidized, they are available only to those who can pay the full cost, RMI said.
10. (SBU) Publicly, Pharmac contends that it delivers the best health-care outcomes possible within the funding
available, citing the fact that the volume of subsidized pharmaceuticals has increased while prices in general have
declined. Pharmac highlights the savings it reaps -- NZ $25 million (US $17.5 million) the past fiscal year -- that
would have been spent on the drug subsidy without its intervention to lower prices. Privately, Wayne McNee, Pharmac's
chief executive officer, acknowledged that the principal obstacle to funding more medicines is the government's
reluctance to increase the pharmaceutical budget. On that, both he and the industry agree.
IPR and advertising under threat
11. (U) U.S. pharmaceutical companies consider New Zealand's patent protection to be inadequate. Pharmac controls
pharmaceutical prices partly through "reference pricing" -- determining the level of subsidy based on the lowest-priced
product in a therapeutic subgroup. The subgroup includes medicines that are similarly effective in treating the same or
similar conditions. This policy often pits patented products against lower-priced generics and does not reward
innovation. Pharmac's general practice is to designate for subsidy only one drug per therapeutic class.
12. (U) The New Zealand government also has refused to extend the effective patent life of drugs, which now stands at
seven years on average (ref A). One U.S. company views the issue as irrelevant, since Pharmac's reference pricing
undermines its patents' commercial value anyway. Most companies see the government's position on effective patent life
as further evidence of its disregard for the pharmaceutical industry.
Further eroding their patents' worth is the so-called springboarding provision in New Zealand's patent law, which allows
generic competitors to start the process of seeking market approval while a proprietary drug is still under patent.
13. (C) In addition, U.S. pharmaceutical companies continue to worry that the government will ban direct-to-consumer
advertising, one of the industry's few pathways around Pharmac's controls (ref C). Several companies, especially those
marketing so-called lifestyle drugs for such conditions as hair loss and erectile dysfunction, have built sales through
advertising. Unsubsidized drugs accounted for 30 percent of sales for Merck Sharp & Dohme, 25 percent for Pfizer, 20 to 25 percent for Pfizer, 20 percent for Johnson & Johnson, 15 percent for Eli Lilly and less than 6 percent for GlaxoSmithKline this year in New Zealand. Health Minister
Annette King and Pharmac oppose direct-to-consumer advertising (DTCA) partly because they believe it tends to increase
expenditures on pharmaceuticals. DTCA also pressures Pharmac to explain why it does not fund certain advertised drugs.
Companies are wary of the New Zealand government using a joint regulatory agency it is establishing with Australia as a
vehicle for banning DTCA, which is not allowed in Australia. However, the Australian High Commission told post that such
a decision is for the New Zealand government alone to make.
A big hit on industry
14. (U) From Pharmac's pricing policies to the government's positions on intellectual property and direct-to-consumer
advertising, U.S. pharmaceutical companies consider New Zealand to be hostile ground. Unable to meet their sales and
profit targets, they say it is becoming increasingly difficult to persuade their home offices to keep investments or
even a presence in the country.
15. (C) As a result, almost all U.S. companies in New Zealand have scaled back their staffs and their
research-and-development investments since Pharmac was formed in 1993. During the past year, Eli Lilly cut 20 percent of
its staff to 27 people, from a peak of 70 employees in the mid-1990s. GlaxoSmithKline has reduced its staff by 65
percent, down to about 50 people. Pfizer downsized its pharmaceutical division by 15 percent, to 60 people. Johnson & Johnson two years ago cut its staff by 10 percent, and Jan Trotman, its general manager in New Zealand, said that if
conditions do not improve in 2005, the company could leave the country in three to five years. (Some staff cuts are due
to the shifting of regulatory oversight from New Zealand to Australia with the scheduled launch of the trans-Tasman
agency in July 2005.) The exception is Merck, where employment has remained stable and sales have increased, partly
because of its higher sales of vaccines.
16. (C) Because of the difficult environment, all the companies have reduced -- and, in some cases, ceased -- investment
in research and development in New Zealand (ref B). Eli Lilly is completing two clinical trials, but otherwise has
transferred all its research and development. Ten years ago, every U.S. drug company in New Zealand employed a medical
director. Now, only Merck has one.
Ironically, New Zealand presents a small but optimal environment for clinical trials of pharmaceuticals because of its
population's lack of exposure to newer medicines. Minister King had threatened to end clinical trials unless patients
participating in a trial had free, lifetime access to the medicine once the trial ended. Other cabinet ministers told
her to stop making that threat.
17. (SBU) Nearly every company said it was holding out some of its newer medicines from New Zealand because of the
expectation that prices and sales volumes would be too low. For the New Zealand consumer, the result is less access to
modern medicines.
Times they are a-changin'?
18. (SBU) Pharmaceutical companies see ideological opposition to their industry in comments by Prime Minister Clark,
Health Minister King and other cabinet members. One pharmaceutical executive recalled how, upon simply introducing
himself at a public forum, the Prime Minister said the drug industry needed to be "stopped" from making excessive
profits. (The industry may be paying a price for its unsuccessful effort in 1990 to unseat Clark, who at the time was
health minister.)
Health Minister King has publicly equated the pharmaceutical industry with the tobacco industry. When several companies
warned her that her government's policies would force the industry out of New Zealand, she responded that she was not
concerned because New Zealand could always shop overseas for its drugs.
19. (SBU) Amid such perceived hostility, there have been subtle changes. In the past couple years, RMI and Pharmac have
worked to maintain dialogue, although RMI in recent months under a new chairman -- a general practitioner -- has more
aggressively promoted the industry's views in the media. While drug companies remain unhappy with Pharmac's practices,
they see capped government funding, rather than Pharmac itself, as their primary problem. Several companies noted an
emerging public debate over access to medicines, a discussion that was nonexistent even a couple years ago.
Public attitudes are changing slowly. As Alister Brown, Merck New Zealand's chief executive, noted, consumers five years
ago assumed that if Pharmac did not fund a drug, it was not worth having. An increasing number of consumers are now
willing to pay for non-subsidized drugs.
20. (C) Finding that its direct pressure failed to alter the government mindset, the industry is now firing up pressure
from below. For the last six months, RMI has been working with patient groups to make them aware of cutting-edge
pharmaceuticals that are not being subsidized in New Zealand.
Lesley Clarke, RMI's chief executive officer, hopes this effort will result in increased pressure on the government to
hike funding for drugs. Although Clarke said it would be too early to see results of RMI's efforts, New Zealand
newspapers in recent months have reported complaints by patient groups over the lack of funding for drugs to treat
breast cancer, Alzheimer's disease, and growth hormone problems.
21. (SBU) New Zealand's doctors would appear to be likely cheerleaders for greater access to pharmaceuticals. However,
industry market research shows that fewer than 20 percent of New Zealand's doctors would tell their patients of
non-funded alternatives to subsidized medications. The drug companies contend that doctors are reluctant to publicly
call for change.
22. (C) A possible U.S.-New Zealand free-trade agreement (FTA) offers one last avenue for changing government policies
that limit access to pharmaceuticals, several U.S. companies said. Meanwhile, Geoff Dangerfield, chief executive of the
New Zealand Ministry of Economic Development, told a U.S. drug company that his government terminated its study of
patent term extension for pharmaceuticals to keep the issue as a bargaining chip in the event of FTA negotiations. If
FTA talks go forward, most of the drug companies will be looking to the U.S. government to win serious concessions from
New Zealand on pharmaceutical issues. Pfizer, which withdrew from RMI early this year, will oppose free-trade
negotiations until the New Zealand government alters some of its policies, especially its patent law and reference
pricing.
Post's strategy
23. (SBU) The challenge is compounded by New Zealand's escalating health-care costs and an aging population. Overall
health-care spending has risen faster than any government budget category since 1994 and now comprises about 20 percent
of the government budget. In the meantime, the government's effort to reduce the cost of seeing a doctor has led to more
patient visits, more prescriptions, and more purchased pharmaceuticals. As a result, Bruce of Pharmac said his agency
would face more pressure to ration its budget or seek a larger portion of the already stressed health budget.
24. (C) To complement the industry's efforts, post will work with companies to identify U.S. speakers to be brought to
New Zealand and possible International Visitor Program participants, with the goal of educating New Zealand's health
practitioners, policymakers and consumers on pharmaceuticals' role in health care. These programs will emphasize the
advantages of expanded access to medicines and treatment options and the link between pharmaceutical research and
development and the biotechnology industry, which the New Zealand government prominently supports as a means to economic
growth. By keeping drug expenses artificially low, the New Zealand government is denying consumers access to many modern
medicines and failing to bear an equitable portion of the cost of developing drugs. Over the long term, post hopes its
efforts will help New Zealand strike a balance between providing affordable medicines and supporting an industry that
creates cures for disease.
Swindells
ENDS